| Literature DB >> 27136058 |
Scott C Ritchie1, Peter Würtz2, Artika P Nath3, Gad Abraham1, Aki S Havulinna4, Liam G Fearnley1, Antti-Pekka Sarin5, Antti J Kangas2, Pasi Soininen6, Kristiina Aalto7, Ilkka Seppälä8, Emma Raitoharju8, Marko Salmi9, Mikael Maksimow9, Satu Männistö10, Mika Kähönen11, Markus Juonala12, Samuli Ripatti13, Terho Lehtimäki8, Sirpa Jalkanen7, Markus Perola4, Olli Raitakari14, Veikko Salomaa10, Mika Ala-Korpela15, Johannes Kettunen16, Michael Inouye17.
Abstract
The biomarker glycoprotein acetylation (GlycA) has been shown to predict risk of cardiovascular disease and all-cause mortality. Here, we characterize biological processes associated with GlycA by leveraging population-based omics data and health records from >10,000 individuals. Our analyses show that GlycA levels are chronic within individuals for up to a decade. In apparently healthy individuals, elevated GlycA corresponded to elevation of myriad inflammatory cytokines, as well as a gene coexpression network indicative of increased neutrophil activity, suggesting that individuals with high GlycA may be in a state of chronic inflammatory response. Accordingly, analysis of infection-related hospitalization and death records showed that increased GlycA increased long-term risk of severe non-localized and respiratory infections, particularly septicaemia and pneumonia. In total, our work demonstrates that GlycA is a biomarker for chronic inflammation, neutrophil activity, and risk of future severe infection. It also illustrates the utility of leveraging multi-layered omics data and health records to elucidate the molecular and cellular processes associated with biomarkers.Entities:
Year: 2015 PMID: 27136058 DOI: 10.1016/j.cels.2015.09.007
Source DB: PubMed Journal: Cell Syst ISSN: 2405-4712 Impact factor: 10.304